Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer...( HUNTINGTON BEACH California and AMSTE...),Health

HUNTINGTON BEACH, California and AMSTERDAM, December 8 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that leading Agendia and the Netherlands Cancer Institute researchers will present data from multiple studies at the 2008 San Antonio Breast Cancer Symposium (SABCS) and Agendia will support, with an unrestricted grant, the New Frontiers in Individualized Breast Cancer Therapy symposium. The San Antonio Breast Cancer Symposium, one of the premiere conferences in breast cancer research worldwide, takes place December 10th-14th, 2008.

The New Frontiers in Individualized Breast Cancer Therapy symposium, an important continuing medical education event at the SABCS, will take place on Saturday, December 13, from 7:30-10 pm, at the Grand Hyatt, San Antonio. Additionally, a mini-symposium and a series of poster presentations will highlight results from studies analyzing Agendia's MammaPrint(R), a FDA-cleared test that identifies the risk of breast cancer recurrence and provides doctors with the rationale to assess the benefits of chemotherapy.

Full study results will be discussed at a mini-symposium and the following embargoed poster sessions and discussions:

    Thursday, 12/11/08, 5:30pm - 7:30pm
    #1063, Poster Session 1: Prognostic Factors and Biomarkers -
    Clinical Testing and Validation, "The 70-gene prognosis profile predicts
    early metastases in postmenopausal breast cancer patients." Presenter:
    Stella Mook, MD, Netherlands Cancer Institute.

    Thursday, 12/11/08, 5:30pm - 7:30pm CST
    #1084, Poster Session 1: Prognostic Factors and Biomarkers -
    Clinical Testing and Validation, "Benefit of the 70-gene profile for
    widely used guidelines: an answer to increased selection for adjuvant
    chemotherapy in breast cancer." Presenter: Michael Knauer, M.D.,
    Netherlands Cancer Institute.

    Friday, 12/12/08, 2pm - 3:30pm CST
    Mi
'/>"/>
SOURCE  Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 
Related medicine technology :

1. Agendias MammaPrint(R) Included in 2008 Dutch Institute for Healthcare Improvement CBO Guidelines
2. Agendia Launches TargetPrint(R) for Breast Cancer Patients
3. APTA Supports Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
4. Analysis of Earlier European Stroke Trial Supports Treatment Regimen for Viprinex(TM) in Current International Phase 3 Clinical Trials
5. DSMB Again Supports Continuation of Alimera Sciences Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
6. New Data Presented at WCTRIMS* Supports the Importance of Early and Sustained Treatment with Betaseron(R)
7. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
8. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
9. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
10. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
11. International Diabetes Federation Grant Supports Lifestyle Intervention Study to Prevent Type 2 Diabetes in India